LetterDear Editor,We recently scrutinized the article titled “Modified G-CSF/ATG-Based Haploidentical Transplantation Protocol in Pediatric Primary Hemophagocytic Lymphohistiocytosis: A Long-Term Follow-Up Single-Center Experience.’ ’ [1]. After thoroughly reviewing it, we sincerely appreciate the authors’ hard work and diligence toward this critical topic. However, we also believe that there are some limitations which, if elaborated upon, could render the article more robust and further strengthen its findings and conclusions.Firstly, although the authors acknowledge the need for future multicenter studies, they do not elaborate on the limitations associated with the single-center nature of their research. This restricts the diversity of patient demographics, genetic subtypes, and clinical presentations represented in the cohort. Additionally, the study’s retrospective design introduces potential bias in patient selection. The relatively small cohort of pediatric patients with Primary Hemophagocytic Lymphohistiocytosis (HLH) further limits the reliability of the results and the ability to detect rare outcomes. In contrast, a multicenter, prospective study from 2012 that reported outcomes using the HLH-2004 protocol in pediatric HLH patients undergoing hematopoietic stem cell transplantation (HSCT) [2] provides more generalized and credible results. Moreover, the authors do not address the inconsistency in treatment and follow-up arising from using a modified, center-specific protocol rather than a standardized treatment regimen. Furthermore, the present study’s absence of a control group precludes comparison with patients who did not receive haploidentical stem cell transplant (HSCT) or those treated with alternative therapeutic approaches. As a result, the overall effectiveness of the haploidentical transplantation technique cannot be definitively assessed, compromising the robustness of the study’s conclusions. The study has the potential to shed light on possible long-term effects—such as neurocognitive, psychosocial, and endocrine outcomes—in patients who received the modified G-CSF/ATG-based haploidentical transplantation protocol in pediatric primary HLH. These long-term outcomes are critical for a comprehensive understanding of the actual benefits of the regimen post-transplant. To ensure that patients can attain normal adulthood, it is essential to determine whether this procedure has no or minimal adverse effects on cognitive function, psychosocial well-being, and pubertal development. Ultimately, preserving our patients’ overall health and quality of life should remain our primary goal as physicians [3]. Lastly, the authors do not address the potential impact of pretransplant treatments, which may significantly influence post-transplant outcomes. Other studies that have explored standard HLH protocols—such as HLH-94, HLH-2004, or Euro-HIT-HLH—and examined the role of treatments like corticosteroids in the pre-transplant phase offer valuable insights into how these predisposing factors affect the overall success of post-transplant therapy [4].Addressing these limitations in future research will provide more meaningful insights into the treatment of pediatric primary HLH using the modified granulocyte colony-stimulating factor (G-CSF)/anti-thymocyte globulin (ATG)–based haploidentical transplantation protocol, ultimately contributing to the advancement of more effective therapeutic strategies that will help us gain a better understanding of this disease, therefore, rendering us to able to be better clinicians who can come up with a more comprehensive and effective regimen for their patients.